$BCDA
BioCardia, Inc.

2019 Q1 Form 10-K Financial Statement

#000143774919006300 Filed on April 02, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q4 2018
Revenue $216.0K $100.0K $625.0K
YoY Change 8.54% 0.0% 30.48%
Cost Of Revenue $106.0K $120.0K $517.0K
YoY Change -32.48% -29.41% -25.07%
Gross Profit $110.0K -$10.00K $108.0K
YoY Change 161.9% -85.71% -151.18%
Gross Profit Margin 50.93% -10.0% 17.28%
Selling, General & Admin $1.631M $1.440M $5.757M
YoY Change -4.45% -14.79% -9.98%
% of Gross Profit 1482.73% 5330.56%
Research & Development $2.166M $2.210M $8.453M
YoY Change 10.79% 24.86% 45.77%
% of Gross Profit 1969.09% 7826.85%
Depreciation & Amortization $23.00K $20.00K $88.00K
YoY Change 4.55% 0.0% 12.82%
% of Gross Profit 20.91% 81.48%
Operating Expenses $3.797M $3.640M $14.21M
YoY Change 3.69% 5.51% 16.53%
Operating Profit -$3.687M -$3.650M -$14.10M
YoY Change 1.85% 3.69% 13.68%
Interest Expense $20.00K $20.00K
YoY Change -50.0% -50.0%
% of Operating Profit
Other Income/Expense, Net $22.00K $0.00 $115.0K
YoY Change -38.89% 18.56%
Pretax Income -$3.670M -$3.640M -$13.99M
YoY Change 2.51% 4.3% 13.65%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.665M -$3.640M -$13.99M
YoY Change 2.26% 4.3% 13.64%
Net Earnings / Revenue -1696.76% -3640.0% -2237.92%
Basic Earnings Per Share
Diluted Earnings Per Share -$756.7K -$844.5K -$3.284M
COMMON SHARES
Basic Shares Outstanding 43.63M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.840M $5.360M $5.360M
YoY Change -70.57% -57.76% -57.76%
Cash & Equivalents $2.838M $5.358M $5.360M
Short-Term Investments
Other Short-Term Assets $290.0K $450.0K $450.0K
YoY Change 3.57% 32.35% 32.35%
Inventory $118.0K $141.0K $140.0K
Prepaid Expenses $445.0K
Receivables $287.0K $274.0K $270.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.528M $6.218M $6.220M
YoY Change -65.43% -53.3% -53.3%
LONG-TERM ASSETS
Property, Plant & Equipment $175.0K $145.0K $150.0K
YoY Change 15.13% -14.2% -11.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $54.00K $54.00K $50.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $1.629M $199.0K $200.0K
YoY Change 690.78% -10.76% -9.09%
TOTAL ASSETS
Total Short-Term Assets $3.528M $6.218M $6.220M
Total Long-Term Assets $1.629M $199.0K $200.0K
Total Assets $5.157M $6.417M $6.420M
YoY Change -50.47% -52.6% -52.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.139M $743.0K $1.020M
YoY Change 54.34% -17.63% 13.33%
Accrued Expenses $596.0K $127.0K $1.530M
YoY Change 2.94% -72.69% 183.33%
Deferred Revenue $118.0K $112.0K
YoY Change 83.61%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.323M $2.548M $2.550M
YoY Change 56.67% 9.26% 9.44%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.020M $80.00K $80.00K
YoY Change 1175.0% 0.0% 0.0%
Total Long-Term Liabilities $1.020M $80.00K $80.00K
YoY Change 1175.0% 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.323M $2.548M $2.550M
Total Long-Term Liabilities $1.020M $80.00K $80.00K
Total Liabilities $4.339M $2.625M $2.630M
YoY Change 96.87% 8.79% 9.13%
SHAREHOLDERS EQUITY
Retained Earnings -$90.03M -$86.36M
YoY Change 18.47% 19.2%
Common Stock $44.00K $5.000K
YoY Change 15.79% -86.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $818.0K $3.792M $3.790M
YoY Change
Total Liabilities & Shareholders Equity $5.157M $6.417M $6.420M
YoY Change -50.47% -52.6% -52.58%

Cashflow Statement

Concept 2019 Q1 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$3.665M -$3.640M -$13.99M
YoY Change 2.26% 4.3% 13.64%
Depreciation, Depletion And Amortization $23.00K $20.00K $88.00K
YoY Change 4.55% 0.0% 12.82%
Cash From Operating Activities -$2.465M -$3.250M -$11.07M
YoY Change -18.81% 28.97% 27.66%
INVESTING ACTIVITIES
Capital Expenditures $55.00K -$20.00K $66.00K
YoY Change 1000.0% -33.33% -51.47%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$55.00K -$20.00K -$66.00K
YoY Change 1000.0% -101.13% -51.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.790M 3.804M
YoY Change 3345.45% 2541.67%
NET CHANGE
Cash From Operating Activities -2.465M -3.250M -11.07M
Cash From Investing Activities -55.00K -20.00K -66.00K
Cash From Financing Activities 3.790M 3.804M
Net Change In Cash -2.520M 520.0K -7.331M
YoY Change -17.0% -181.25% -15.38%
FREE CASH FLOW
Cash From Operating Activities -$2.465M -$3.250M -$11.07M
Capital Expenditures $55.00K -$20.00K $66.00K
Free Cash Flow -$2.520M -$3.230M -$11.14M
YoY Change -17.13% 29.72% 26.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 bcda Cash Acquired In Reverse Merger
CashAcquiredInReverseMerger
CY2017 bcda Cash Acquired In Reverse Merger
CashAcquiredInReverseMerger
CY2016 bcda Cash Acquired In Reverse Merger
CashAcquiredInReverseMerger
19017000
CY2018 bcda Change In Fair Value Of Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
CY2017 bcda Change In Fair Value Of Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
CY2016 bcda Change In Fair Value Of Convertible Preferred Stock Warrant Liability
ChangeInFairValueOfConvertiblePreferredStockWarrantLiability
250000
CY2018Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1528000
CY2017Q4 bcda Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1263000
CY2018Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
276000
CY2017Q4 bcda Accured Clinical Trial Costs
AccuredClinicalTrialCosts
74000
CY2016 bcda Adjustments To Additional Paid In Capital Reclassification Of Convertible Shareholder Notes Derivative Liability
AdjustmentsToAdditionalPaidInCapitalReclassificationOfConvertibleShareholderNotesDerivativeLiability
2268000
CY2017 bcda Payments Of Transaction Costs For Reverse Merger
PaymentsOfTransactionCostsForReverseMerger
CY2016 bcda Payments Of Transaction Costs For Reverse Merger
PaymentsOfTransactionCostsForReverseMerger
96000
CY2018 bcda Change In Fair Value Of Convertible Shareholder Notes Derivative Liability
ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability
CY2017 bcda Change In Fair Value Of Convertible Shareholder Notes Derivative Liability
ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability
CY2016 bcda Change In Fair Value Of Convertible Shareholder Notes Derivative Liability
ChangeInFairValueOfConvertibleShareholderNotesDerivativeLiability
-1224000
CY2018 bcda Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability
ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability
CY2017 bcda Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability
ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability
CY2016 bcda Change In Fair Value Of Maturity Date Preferred Stock Warrant Liability
ChangeInFairValueOfMaturityDatePreferredStockWarrantLiability
10000
CY2016 bcda Conversion Of Preferred Stock Into Common Stock Value
ConversionOfPreferredStockIntoCommonStockValue
CY2018Q4 bcda Deferred Tax Assets Net Operating Loss And Tax Credit Carryforwards Noncurrent
DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwardsNoncurrent
20698000
CY2017Q4 bcda Deferred Tax Assets Net Operating Loss And Tax Credit Carryforwards Noncurrent
DeferredTaxAssetsNetOperatingLossAndTaxCreditCarryforwardsNoncurrent
17368000
CY2018 bcda Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestAmount
CY2017 bcda Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestAmount
CY2016 bcda Effective Income Tax Rate Reconciliation Nondeductible Expense Interest Amount
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestAmount
590000
CY2018 bcda Effective Income Tax Rate Reconciliation Warrant And Derivative Revaluation Amount
EffectiveIncomeTaxRateReconciliationWarrantAndDerivativeRevaluationAmount
CY2017 bcda Effective Income Tax Rate Reconciliation Warrant And Derivative Revaluation Amount
EffectiveIncomeTaxRateReconciliationWarrantAndDerivativeRevaluationAmount
CY2016 bcda Effective Income Tax Rate Reconciliation Warrant And Derivative Revaluation Amount
EffectiveIncomeTaxRateReconciliationWarrantAndDerivativeRevaluationAmount
328000
CY2018 bcda Exchange Of Convertible Preferred Stock Warrants For Common Stock
ExchangeOfConvertiblePreferredStockWarrantsForCommonStock
CY2017 bcda Exchange Of Convertible Preferred Stock Warrants For Common Stock
ExchangeOfConvertiblePreferredStockWarrantsForCommonStock
CY2016 bcda Exchange Of Convertible Preferred Stock Warrants For Common Stock
ExchangeOfConvertiblePreferredStockWarrantsForCommonStock
25000
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2018Q4 bcda Grant Liability Current
GrantLiabilityCurrent
645000
CY2017Q4 bcda Grant Liability Current
GrantLiabilityCurrent
663000
CY2018 bcda Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
3800000
CY2018 bcda Payments Of Transaction Costs For Reverse Merger
PaymentsOfTransactionCostsForReverseMerger
CY2018Q4 bcda Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3800000
CY2018 bcda Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3800000
CY2017 bcda Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
CY2016 bcda Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
CY2018 bcda Proceeds From Issuance Of Convertible Notes And Warrants
ProceedsFromIssuanceOfConvertibleNotesAndWarrants
CY2017 bcda Proceeds From Issuance Of Convertible Notes And Warrants
ProceedsFromIssuanceOfConvertibleNotesAndWarrants
CY2016 bcda Proceeds From Issuance Of Convertible Notes And Warrants
ProceedsFromIssuanceOfConvertibleNotesAndWarrants
4374000
CY2018 bcda Reclassification Of Convertible Shareholder Notes Derivative Liability
ReclassificationOfConvertibleShareholderNotesDerivativeLiability
CY2017 bcda Reclassification Of Convertible Shareholder Notes Derivative Liability
ReclassificationOfConvertibleShareholderNotesDerivativeLiability
CY2016 bcda Reclassification Of Convertible Shareholder Notes Derivative Liability
ReclassificationOfConvertibleShareholderNotesDerivativeLiability
2268000
CY2018 bcda Standard Product Warranty Term
StandardProductWarrantyTerm
P2Y
CY2016 bcda Stock Issued During Period Value Exchange Of Convertible Preferred Stock Warrants To Common Stock
StockIssuedDuringPeriodValueExchangeOfConvertiblePreferredStockWarrantsToCommonStock
25000
CY2016 bcda Stock Issued During Period Value Recapitalization For Reverse Merger
StockIssuedDuringPeriodValueRecapitalizationForReverseMerger
18921000
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43631684
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018Q2 dei Entity Public Float
EntityPublicFloat
27400314
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1020000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
902000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
274000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
95000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
495000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
465000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
845000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
758000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
90110000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
83537000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
942000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2707000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2774000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2774000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2707000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
942000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
9000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8411389
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4311096
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3491937
CY2018Q4 us-gaap Assets
Assets
6417000
CY2017Q4 us-gaap Assets
Assets
13538000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
6218000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
13315000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5358000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12689000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21352000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3557000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7331000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-8663000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
17795000
CY2018Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.75
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
0.5
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2666666
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43611240
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38218660
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5333332
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43611240
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38218660
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
38000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
12884000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
8184000
CY2017Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
76000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
146000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
84000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
110000
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2016 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
12156000
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"><tr style="vertical-align: top;"><td style="width: 27pt;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(e)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Concentration of Credit Risk</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 31, 2018, </div>the Company&#x2019;s cash was held by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> financial institution and the amount on deposit was in excess of FDIC insurance limits. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> recognized any losses from credit risks on such accounts since inception. The Company believes it is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> exposed to significant credit risk on cash.</div></div></div></div></div></div></div>
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
112000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
61000
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2017 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
CY2016 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
46030000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
517000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
690000
CY2016 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
746000
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
14727000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
77000
CY2017Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
81000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
167000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
21831000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
18665000
CY2018Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
276000
CY2017Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
449000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
12000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
34000
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
113000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
558000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21831000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18665000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
0
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2018 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
26000
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
648000
CY2017 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.75
CY2018 us-gaap Depreciation
Depreciation
88000
CY2017 us-gaap Depreciation
Depreciation
78000
CY2016 us-gaap Depreciation
Depreciation
39000
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
88000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
78000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
39000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.32
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3166000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-2937000
CY2017 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-4185000
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-3505000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
440000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
344000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
136000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
22000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
7000
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
94000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-2965000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2761000
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2017 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
8172000
CY2016 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-455000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1238000
CY2016 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-315000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
236000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
135000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
89000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
119000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
377000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-17000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
179000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
21000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-33000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
240000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
415000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
530000
CY2018 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-4000
CY2017 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
25000
CY2016 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
26000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-65000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
96000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
32000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-49000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
56000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-27000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
11000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
104000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
110000
CY2018 us-gaap Interest Expense
InterestExpense
CY2017 us-gaap Interest Expense
InterestExpense
CY2016 us-gaap Interest Expense
InterestExpense
1736000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
23000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
29000
CY2018Q4 us-gaap Inventory Net
InventoryNet
141000
CY2017Q4 us-gaap Inventory Net
InventoryNet
191000
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
79000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
70000
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
39000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
92000
CY2018 us-gaap Inventory Write Down
InventoryWriteDown
CY2017 us-gaap Inventory Write Down
InventoryWriteDown
CY2016 us-gaap Inventory Write Down
InventoryWriteDown
597000
CY2016Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2018Q4 us-gaap Liabilities
Liabilities
2625000
CY2017Q4 us-gaap Liabilities
Liabilities
2413000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6417000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13538000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2548000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2332000
CY2016 us-gaap Other Operating Income
OtherOperatingIncome
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
CY2018 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Contingencies</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> aware of any current legal or administrative proceedings that are likely to have a material effect on the Company&#x2019;s business, financial position, results of operations, or cash flows.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div></div>
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3804000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
144000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4396000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-136000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18921000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11069000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8671000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5522000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-13987000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-12308000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-10310000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
115000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
97000
CY2016 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2702000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-14102000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-12405000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-7608000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1891000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
612000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
649000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
630000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
601000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
321000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
601000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
54000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2018 us-gaap Other Operating Income
OtherOperatingIncome
118000
CY2017 us-gaap Other Operating Income
OtherOperatingIncome
95000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
1736000
CY2018Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
200000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
200000
CY2017 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
CY2016 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
66000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
136000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
CY2018 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2017 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
1800000
CY2016 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
445000
CY2017Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
340000
CY2018 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2017 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
1800000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
144000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
22000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
990000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
927000
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
479000
CY2016 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
576000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1890000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
400000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
144000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
431700
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1698452
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.72
CY2018 us-gaap Property Plant And Equipment Impairment
PropertyPlantAndEquipmentImpairment
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"><tr style="vertical-align: top;"><td style="width: 27pt;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">i</div></div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Long-Lived Assets</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">The carrying value of long-lived assets, including property and equipment, is reviewed for impairment whenever events or changes in circumstances indicate that the asset <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. An impairment loss is recognized when the total of estimated future undiscounted cash flows, expected to result from the use of the asset and its eventual disposition, are less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. Through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> there have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> such impairment losses</div></div></div></div></div></div></div>
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
169000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2346990
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.72
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8453000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5799000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3330000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-86361000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-72450000
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
625000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3000
CY2018Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
0.75
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.80
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.33
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5757000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6395000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4108000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2774000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
2707000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
942000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4213100
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5477364
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.96
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.80
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.80
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.92
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.41
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y328D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y36D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y292D
CY2017Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
0
CY2018Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
0
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2488
CY2016 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12156000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2017 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
144000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
-3442000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
20582000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
11125000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3792000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
725000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
608000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
891000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
166000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
117000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
CY2018Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
636000
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
511000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"><tr style="vertical-align: top;"><td style="width: 27pt;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(c)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The preparation of the financial statements in accordance with U.S. GAAP requires Company management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property and equipment; allowances for doubtful accounts and sales returns; inventory valuation; and share-based compensation.</div></div></div></div></div></div></div>
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3200000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3000000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38377606
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38160543
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8368284

Files In Submission

Name View Source Status
0001437749-19-006300-index-headers.html Edgar Link pending
0001437749-19-006300-index.html Edgar Link pending
0001437749-19-006300.txt Edgar Link pending
0001437749-19-006300-xbrl.zip Edgar Link pending
bcda-20181231.xml Edgar Link completed
bcda-20181231.xsd Edgar Link pending
bcda-20181231_cal.xml Edgar Link unprocessable
bcda-20181231_def.xml Edgar Link unprocessable
bcda-20181231_lab.xml Edgar Link unprocessable
bcda-20181231_pre.xml Edgar Link unprocessable
bcda20181231_10k.htm Edgar Link pending
bcda_image1.jpg Edgar Link pending
ex_138958.htm Edgar Link pending
ex_139075.htm Edgar Link pending
ex_139076.htm Edgar Link pending
ex_139077.htm Edgar Link pending
ex_139078.htm Edgar Link pending
ex_139079.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending